.Net Biotechnology Development Software 
GeekWire
FEBRUARY 15, 2022
Adaptive Biotechnologies , which develops technology to assess the immune response, posted $154.3 Net loss for 2021 came in at $207.3 million in the fourth quarter, up 26%, with a net loss of $61.4 Tests for five autoimmune and inflammatory conditions, including Crohn’s disease, are in earlier stages of development.
GeekWire
FEBRUARY 8, 2021
Nautilus Biotechnology co-founders Sujal Patel (left) and Parag Mallick. Nautilus Biotechnology , a Seattle-based biotech startup led by Isilon co-founder Sujal Patel , is the latest company to go public using a special purpose acquisition company, or SPAC. Nautilus Photo). It values the company at $900 million.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
GeekWire
JUNE 9, 2021
Nautilus Biotechnology co-founders Sujal Patel (left) and Parag Mallick. Nautilus Biotechnology is emerging as Seattle’s newest publicly traded company this week, taking advantage of the mania over SPACs to raise $345 million to fuel a new approach that could accelerate biomedical research and transform drug development.
GeekWire
AUGUST 23, 2021
In a region better known for its tech startups and legions of software engineers, it’s biotech companies that have helped lead a recent IPO boom in the state of Washington, accounting for eight of 11 firms joining the public markets via a traditional IPO over the past year. based biotech company went public. Absci Photo).
GeekWire
SEPTEMBER 17, 2020
Founded in 2011, Athira is in late-stage development for its lead therapeutic candidate called NDX-1017. Formerly known as M3 Biotechnology, the company is led by Dr. Leen Kawas , a 35-year-old CEO who will be the first woman to guide a company to an initial public offering in Washington state in more than two decades.
GeekWire
AUGUST 26, 2020
The Seattle biotech filed initial IPO paperwork Wednesday, a surprising move that would give the company additional capital to develop its therapies for brain diseases. Founded in 2011, Athira is in late-stage development for its lead therapeutic candidate called NDX-1017. In its IPO paperwork, Athira reports a net loss of $5.2
GeekWire
SEPTEMBER 18, 2020
It’s the latest privately-held company to test the public markets amid a rush of IPOs in recent months, particularly in biotech and software , despite the ongoing pandemic. Founded in 2011, Athira is in late-stage development for its lead therapeutic candidate called NDX-1017. The stock was up slightly in Friday morning trading.
Expert insights. Personalized for you.
89 
Let's personalize your content